Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment
- 1 April 2008
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (4), 445-454
- https://doi.org/10.1177/0091270007313390
Abstract
Levosimendan is a vasodilator used in the treatment of acute heart failure. In the present study, the effect of hepatic impairment on the pharmacokinetics of levosimendan and its 2 metabolites, OR-1855 and OR-1896 (pharmacologically active), was investigated in 12 healthy subjects and 12 subjects with moderate hepatic impairment due to alcoholic cirrhosis of the liver but with no heart failure. In addition, the effect of acetylator status on the pharmacokinetics of levosimendan, OR-1855, and OR-1896 was evaluated. Safety and tolerability of levosimendan were also assessed. Levosimendan was given as an intravenous infusion of 0.1 microg/kg/min for 24 hours. Levosimendan showed similar C(max), AUC, and elimination half-life (t(1/2)), with a mean (+/-SEM) t(1/2) of 0.9 +/- 0.0 hours in healthy subjects and 0.8 +/- 0.1 hours in hepatically impaired subjects, respectively (not significant). The t(1/2) of OR-1855 was 61 +/- 5 hours in healthy subjects and 82 +/- 3 hours (P < .01) in subjects with hepatic impairment. The t(1/2) of OR-1896 was 62 +/- 5 hours and 91 +/- 5 hours (P < .01), respectively. However, the AUCs of OR-1855 and OR-1896 were similar in healthy volunteers and hepatically impaired subjects. The effect of acetylator status was seen as higher C(max) and AUC of OR-1855 in slow acetylators. Correspondingly, higher C(max) and AUC of OR-1896 were observed in rapid acetylators. Levosimendan was well tolerated in both study groups. In conclusion, the pharmacokinetics of the parent drug levosimendan was unaltered in subjects with moderate hepatic impairment, whereas the elimination of the metabolites was prolonged. However, because the maximum duration of levosimendan infusion is 24 hours, dosing adjustments of levosimendan may not be required in subjects with impaired hepatic function.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of the Vasorelaxing Effect of Cromakalim and the New Inodilator, Levosimendan, in Human Isolated Portal VeinJournal of Pharmacy and Pharmacology, 2000
- Effects of Liver Disease on PharmacokineticsClinical Pharmacokinetics, 1999
- A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.Journal of Medical Genetics, 1997
- MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISMAnnual Review of Pharmacology and Toxicology, 1997
- Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendanJournal of Molecular and Cellular Cardiology, 1995
- Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1995
- Dose-Range Study of a New Calcium Sensitizer, Levosimendan, in Patients with Left Ventricular DysfunctionJournal of Cardiovascular Pharmacology, 1995
- Levosimendan (OR-1259), a Myofilament Calcium Sensitizer, Enhances Myocardial Contractility but Does Not Alter Isovolumic Relaxation in Conscious and Anesthetized DogsAnesthesiology, 1994
- Clinical Pharmacokinetics in Heart FailureClinical Pharmacokinetics, 1988
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973